Viemed Healthcare Posts Record 2025 Results but Shares Dip on Revenue Miss and Cautious 2026 Outlook
Shares of Viemed Healthcare Inc (NASDAQ:VMD) traded lower in after-hours activity following the release of its fourth-quarter and full-year 2025 financial results. The provider of home-based healthcare solutions reported record annual revenue and profit, but a top-line miss for the quarter and a 2026 revenue guidance range that fell short of analyst expectations appeared to temper investor enthusiasm.
Earnings and Revenue Versus Estimates
The company’s quarterly performance presented a mixed picture relative to Wall Street forecasts. Viemed delivered a solid beat on the bottom line but fell short on revenue for the final quarter of 2025.
- Q4 2025 Revenue: $76.2 million, a 26% year-over-year increase.
- Q4 2025 Analyst Revenue Estimate: $78.5 million, resulting in a miss of approximately $2.3 million.
- Q4 2025 EPS (Diluted): $0.14, a 31% increase over Q4 2024.
- Q4 2025 Analyst EPS Estimate: $0.126, representing a beat of approximately 11%.
For the full year 2025, the company reported net revenue of $270.3 million, a 21% increase, and net income attributable to Viemed of $14.9 million, or $0.37 per diluted share, marking a 33% increase and its ninth consecutive year of profitability.
Market Reaction and Forward Guidance
The immediate market reaction, with shares declining over 6% after the bell, suggests investors were focusing on the quarterly revenue miss and the company's initial outlook for 2026. Management provided the following guidance for the year ending December 31, 2026:
- Net Revenue: Expected in the range of $310 million to $320 million.
- Adjusted EBITDA: Expected in the range of $65 million to $69 million.
The midpoint of the revenue guidance range, $315 million, sits below the current analyst consensus estimate of $335.9 million for 2026 sales. This conservative projection, despite strong historical growth, likely contributed to the negative after-hours price action. The company also noted that net capital expenditures are expected to be between 10% and 11.5% of net revenue.
Key Highlights from the 2025 Report
Beyond the headline numbers, Viemed’s press release highlighted several operational strengths and strategic initiatives:
- Strong Cash Generation: The company emphasized its robust free cash flow, which more than doubled to $28.1 million for the full year 2025, up from $11.6 million in 2024. Net cash from operating activities reached $51.9 million.
- Patient Growth: Significant expansion was seen in its sleep therapy and resupply patient counts, which grew by 62% and 49% year-over-year, respectively. The core ventilator patient count increased by 4%.
- Strategic Acquisition: Revenue growth was bolstered by the 2025 acquisition of Lehan's Medical Equipment.
- Capital Return Program: Reflecting confidence in its cash flow durability, the Board authorized a new share repurchase program for 2026. The company repurchased $13.2 million worth of its shares under its previous program in 2025.
- Balance Sheet Health: The company ended the year with $13.5 million in cash, $46 million available under credit facilities, and long-term debt of $11.3 million.
CEO Casey Hoyt attributed the year's success to "the continued strength of our technology-enabled home care model and the growing demand for high-quality chronic care management delivered in the home." COO Todd Zehnder pointed to the strong free cash flow as providing "significant flexibility" for both strategic investments and returning capital to shareholders.
Conclusion
Viemed Healthcare concluded a record 2025 with powerful earnings growth and impressive cash flow conversion. However, the market's initial reaction underscores the weight given to future guidance. While the company continues to execute on its growth strategy—evidenced by strong organic patient growth and a new buyback authorization—its below-consensus revenue outlook for 2026 has introduced a note of caution among investors. The company will host a conference call on March 5, 2026, to discuss the results in greater detail.
For a detailed history of Viemed's earnings and analyst estimates, visit its earnings page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, nor does it recommend any investment action. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
